ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1558

Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study

Thomas Guedens1, Elvira Lesmana2, Adam Edwinson3, Margaret Breen-Lyles1, Anukul Karn4, Madhusudan Grover1 and Ashima Makol3, 1Mayo Clinic, Rochester, Rochester, MN, 2Mayo Clinic, Rochester, USA, Rochester, MN, 3Mayo Clinic, Rochester, MN, 4Trinity Health Livonia, Farmington Hills, MI

Meeting: ACR Convergence 2025

Keywords: diet, Patient reported outcomes, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Systemic sclerosis (SSc) is a rare multisystem auto-immune disease characterized by peripheral vasculopathy and widespread fibrosis of the skin and internal organs. Up to 90% of SSc patients experience gastrointestinal (GI) symptoms ranging from mild to very severe. We aimed to explore how GI symptom severity correlates with dietary intake patterns and patient-reported outcome measures in SSc patients.

Methods: Adult ( >18 years old) SSc patients meeting the ACR/EULAR 2013 criteria were prospectively recruited and stratified into those with none-to-mild and moderate-to-very severe GI symptoms based on The University of California Los Angeles Scleroderma Clinical Trials Consortium gastrointestinal tract 2.0 (UCLA GIT 2.0) scores.1 Patients completed a food frequency questionnaire to assess dietary intake which was compared to historically obtained healthy volunteer dietary data. Patient-reported outcomes were assessed using a range of validated questionnaires. All variables were compared using Mann-Whitney U tests and Kruskal-Wallis tests and correlated using Spearman’s rank correlation.

Results: 94 SSc participants (79 females; mean 58±12 years) were enrolled. The average UCLA GIT 2.0 score was 0.6±0.4 and participants were categorized as having none to mild (n=47, 50%), and moderate to very severe GI symptoms (n=47, 50%). Compared to healthy volunteers or those with none to mild GI symptoms, patients with moderate to very severe GI symptoms had a lower intake of vegetable proteins and empty calories as well as lower healthy eating index (HEI) scores (Table 1). Patients with moderate to very severe GI symptoms also consumed more saturated fatty acids compared to healthy volunteers. Regardless of GI symptoms, SSc patients consumed fewer whole grains compared to healthy volunteers. Additionally, patients with moderate to very severe GI symptoms reported worse physical and social function, higher levels of fatigue, pain and anxiety, and more bowel movements which were also softer when compared to those with none to mild GI symptoms (Table 2). Harder stool consistency correlated with higher HEI scores (r=0.42, p < 0.001) and a higher intake of fiber (r=0.40, p < 0.001) and vegetable protein (r=0.44, p < 0.001).

Conclusion: In this large prospective single center cohort of well characterized SSc patients, those with moderate to very severe GI symptoms exhibited suboptimal dietary intake and reported worse physical and social functioning as well as higher levels of pain, fatigue and anxiety. Future studies are needed to understand the mechanistic influence of diet in SSc patients and its impact on GI symptoms and other patient-reported outcomes.

Supporting image 1

Supporting image 2


Disclosures: T. Guedens: None; E. Lesmana: None; A. Edwinson: None; M. Breen-Lyles: None; A. Karn: None; M. Grover: Alfa-Sigma, 5, Takeda, 5; A. Makol: Amgen, 12, Site PI for Clinical trial, AstraZeneca, 12, Site PI for Clinical trial, Boehringer-Ingelheim, 1, 12, Site PI for Clinical trial, Sanofi Genzyme, 12, Site PI for Clinical trial.

To cite this abstract in AMA style:

Guedens T, Lesmana E, Edwinson A, Breen-Lyles M, Karn A, Grover M, Makol A. Gastrointestinal Symptom Severity Is Associated With Worse Patient-Reported Outcomes And Dietary Patterns In Systemic Sclerosis: A Single Center Prospective Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/gastrointestinal-symptom-severity-is-associated-with-worse-patient-reported-outcomes-and-dietary-patterns-in-systemic-sclerosis-a-single-center-prospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gastrointestinal-symptom-severity-is-associated-with-worse-patient-reported-outcomes-and-dietary-patterns-in-systemic-sclerosis-a-single-center-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology